| Target Price | CN¥33.51 |
| Price | CN¥24.02 |
| Potential |
39.50%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Shanghai Fosun Pharmaceuti-h 2027 .
The average Shanghai Fosun Pharmaceuti-h target price is CN¥33.51.
This is
39.50%
register free of charge
CN¥35.39
47.31%
register free of charge
CN¥25.05
4.28%
register free of charge
|
|
| A rating was issued by 10 analysts: 7 Analysts recommend Shanghai Fosun Pharmaceuti-h to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Shanghai Fosun Pharmaceuti-h stock has an average upside potential 2027 of
39.50%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion CN¥ | 41.66 | 43.26 |
| 1.45% | 3.83% | |
| EBITDA Margin | 11.01% | 14.04% |
| 1.78% | 27.49% | |
| Net Margin | 8.09% | 9.00% |
| 19.95% | 11.24% |
7 Analysts have issued a sales forecast Shanghai Fosun Pharmaceuti-h 2026 . The average Shanghai Fosun Pharmaceuti-h sales estimate is
This results in the following potential growth metrics:
7 Shanghai Fosun Pharmaceuti-h Analysts have issued a net profit forecast 2026. The average Shanghai Fosun Pharmaceuti-h net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CN¥ | 1.27 | 1.46 |
| 22.12% | 14.96% | |
| P/E | 16.48 | |
| EV/Sales | 1.94 |
7 Analysts have issued a Shanghai Fosun Pharmaceuti-h forecast for earnings per share. The average Shanghai Fosun Pharmaceuti-h EPS is
This results in the following potential growth metrics and future valuations:
Shanghai Fosun Pharmaceuti-h...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


